<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>J Antimicrob Chemother <br /> doi:10.1093/jac/dkq103 <br />  <br />  <br />  <br />  <br />     PhoY2 PhoY1 PhoU homologue involved persisters <br />                      Mycobacterium tuberculosis <br />                                                    Wanliang Shi Ying Zhang * <br />  <br />        Department Molecular Microbiology Immunology, Bloomberg School Public Health, Johns Hopkins University, <br />                                                   Baltimore, MD 21205, USA <br />  <br />                        *Corresponding author. Tel: +1-410-614-2975; Fax: +1-410-955-0105; E-mail: yzhang@jhsph.edu <br />  <br />              Received 10 November 2009; returned 22 January 2010; revised 18 February 2010; accepted 5 March 2010 <br />  <br />            Objectives: Mycobacterial persistence thought underlying cause current lengthy tuberculosis <br />            therapy latent infection. Despite recent progress, mechanisms bacterial persistence poorly <br />            understood. We recently identified new persister gene phoU Escherichia coli shown that <br />            phoU mutant defect persisters. The objective study evaluate role phoU <br />            homologues phoY1 phoY2 Mycobacterium tuberculosis mycobacterial persistence. <br />            Methods: M. tuberculosis phoY1 phoY2 mutant strains constructed. The persister-related phenotypes <br />            phoY1 phoY2 mutants assessed vitro MIC testing, drug exposure assays by <br />            <span id='am-8' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-9' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-81' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-82' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-83' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span>survival</span> mouse model tuberculosis infection. <br />            Results: We demonstrated M. tuberculosis PhoY2 equivalent E. coli PhoU inactivation of <br />            phoY2 phoY1 caused defect persistence <span id='am-86' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-87' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-106' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-118' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-129' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-142' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-152' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-160' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span>phenotype</span> shown increased susceptibility rifam- <br />            picin pyrazinamide MIC testing drug exposure assays reduced persistence the <br />            mouse model. <br />            Conclusions: This study provides validation PhoU involved persistence E. coli but <br />            M. tuberculosis implications development new drugs targeting persisters improved <br />            treatment. <br />  <br /> Keywords: mycobacterial persistence, mutants, antibiotics <br />  <br />  <br />  <br />  <br /> Introduction                                                            developing new drugs target persisters shorten <br />                                                                         TB therapy.6,7 <br /> Tuberculosis (TB) leading infectious killer worldwide                   Persisters described Hobby et al. 8 1942 when <br /> despite chemotherapy BCG vaccine. The causative agent               penicillin killed 99% streptococcal culture <br /> Mycobacterium tuberculosis highly successful pathogen,             leaving 1% bacterial population intact. This phenomenon <br /> which latently infected one-third world population           carefully defined Bigger 1944 coined the <br /> and causes 9 million new TB cases 1.6 million deaths                term &#226;&#8364;&#732;persisters&#226;&#8364;&#8482; 1% surviving bacteria killed peni- <br /> worldwide year.1 This global TB situation expected           cillin.9 Although persisters initially defined using log phase <br /> be exacerbated spread HIV infection increasing            cultures contain small number non-growing persisters, <br /> emergence multidrug-resistant TB (MDR-TB) exten-                 <span id='am-3' about='Thesaurus:DEFINITION' typeof='owl:Thing'>definition</span> persisters subsequently extended <span id='am-7' about='protege:TO' typeof='owl:Thing'>to</span> <br /> sively drug-resistant TB (XDR-TB).2 &#226;&#8364;&#8220; 4 Although current TB         include non-growing persisters enriched station- <br /> therapy cure disease, long takes               ary phase cultures.10,11 Thus, antibiotic-tolerant bacteria are <br /> least 6 months. The lengthy TB therapy makes patient compli-            killed antibiotics regrow absence anti- <br /> ance difficult frequently causes selection drug-resistant        biotics remain susceptible antibiotics are <br /> strains. The lengthy TB therapy thought to             called persisters. Persisters characterized slow no <br /> presence mycobacterial persisters effectively           growth low metabolic activity phenotypic resistance <br /> killed current TB drugs.5,6 Due problem                antibiotics.10 The presence persister phenomenon has <br /> drug-resistant persister TB, currently great             documented numerous bacterial species including <br /> deal understanding persister mechanisms              M. tuberculosis.5,6,11 Persisters biofilms bacterial <br />  <br /> # The Author 2010. Published Oxford University Press behalf British Society Antimicrobial Chemotherapy. All rights reserved. <br /> For Permissions, e-mail: journals.permissions@oxfordjournals.org <br />  <br />                                                                                                                                        1237 <br />  Shi Zhang <br />  <br />  <br />  <br /> infections pose significant challenge treatment disease         phenotype complemented functional <br /> control.5,11 Despite original observation persistence          wild-type phoY2 gene. <br /> phenomenon 60 years ago, mechanisms persister for- <br /> mation poorly understood. Recent studies suggest that <br /> toxin &#226;&#8364;&#8220; antitoxin (TA) modules involved persister for- <br />                                                                           Materials methods <br /> mation.11 The TA module linked persistence Escherichia        Bacterial growth conditions <br /> coli HipBA.12 HipB HipA, like TA modules as <br />                                                                           Bacterial strains plasmids used shown Table 1. E. coli strains <br /> RelBE MazEF, organized operon gene <br />                                                                           grown Luria&#226;&#8364;&#8220;Bertani (LB) broth LB broth agar. Mycobacter- <br /> hipB encoding antitoxin, located upstream toxin                ium smegmatis mc2155 grown LB broth containing 0.5% glycerol, <br /> gene hipA.13 Overexpression wild-type toxin HipA            0.5% dextrose 0.05% Tween 80. M. tuberculosis strain H37Rv was <br /> RelE caused 10- 1000-fold persisters.14,15 HipA               grown 7H9 liquid medium (Difco) supplemented 0.05% Tween <br /> RelE inhibit macromolecule (protein, RNA DNA) syn-              80 10% bovine serum albumin&#226;&#8364;&#8220; dextrose&#226;&#8364;&#8220; catalase (ADC) enrich- <br /> thesis slow stop cell division, raising possi-       ment (Difco) 378C  2&#226;&#8364;&#8220; 3 weeks occasional agitation. When <br /> bility toxins TA modules involved persister         required, following antibiotics used specified concen- <br /> formation.11 However, deletion TA modules hipA did             trations: kanamycin (25 mg/L) hygromycin B (150 mg/L E. coli <br /> not cause defect persistence15,16 presumably            50 mg/L M. tuberculosis). <br /> redundancy genome. A recent study showed overex- <br /> pression unrelated toxic proteins, heat shock protein          <span id='am-242' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-243' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-246' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-247' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-250' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-254' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-260' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-264' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-268' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-269' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-270' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-271' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-272' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-273' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-278' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-279' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-292' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-297' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-298' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-300' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-301' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-306' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-307' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-309' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-310' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-312' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-314' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-315' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-316' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-317' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-318' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-319' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span>Knockout</span> mutant construction complementation <br /> DnaJ protein PmrC, caused higher persister formation.17 <br /> This finding questions significance TA modules specific       phoY1 phoY2 genes M. tuberculosis H37Rv disrupted using <br /> and universal mechanism persister formation.                          specialized transduction described previously.20 To create phoY1::hyg <br />                                                                           phoY2::hyg, hygromycin resistance cassette used to <br />     In M. tuberculosis, isocitrate lyase (ICL), required fatty acid <br />                                                                           replace respective gene&#226;&#8364;&#8482;s open reading frames. Successful deletion <br /> catabolism, involved mycobacterial persist-            gene confirmed junction PCR DNA sequencing. For <br /> ence.18 In addition, inactivation RelA led defect persist-     complementation deletion mutants, wild-type phoY1 phoY2 <br /> ence mouse model.19 We recently identified new              genes amplified H37Rv genomic DNA PCR cloned <br /> persister gene phoU, involved persister formation E. coli.16        mycobacterial shuttle vector pMV261 followed electroporation <br /> PhoU negative regulator pst operon involved phos-          mutants described previously.21 Primers used construct <br /> phate uptake function known. We recently showed            phoY1 phoY2 mutants complementation shown Table 1. <br /> that inactivation phoU E. coli leads dramatic defect in <br /> persister phenotype demonstrated reduced persister <br /> numbers persister assays increased susceptibility a <br />                                                                           MIC/MBC determination drug exposure assays <br /> diverse range antibiotics stress conditions (acid pH, star-        The MICs isoniazid rifampicin determined using serial <br /> vation, etc.), especially stationary phase starved cultures         2-fold dilutions compound 7H9 medium 7H11 agar. <br /> compared log phase cultures.16 Microarray studies indicated          The MIC pyrazinamide determined 7H9 medium 7H11 <br /> that E. coli phoU mutant surprisingly expressed high levels        agar pH 5.6. The initial cell density 105 cfu/mL log phase <br />                                                                           culture, samples incubated 15 days 378C. The MIC <br /> genes involved energy production metabolism, efflux/ <br />                                                                           recorded minimum drug concentration prevented <br /> transport, flagella chemotaxis synthesis, suggesting <br />                                                                           visible growth, MBC recorded drug concentration <br /> that PhoU global repressor cellular metabolism           reduced cfu 100-fold seeded inoculum MIC <br /> inactivation leads hyperactive metabolic state under-         testing. <br /> lying cause persistence defect. This study provides          For drug exposure persister assays, survival stationary phase <br /> evidence PhoU master regulator, role             cultures phoY1 phoY2 mutants wild-type H37Rv to <br /> phosphate metabolism, involved persister formation.              pyrazinamide (200 mg/L) rifampicin (8 mg/L) determined. <br /> We proposed model based PhoU serves                   Drug exposure pyrazinamide performed acidic medium <br /> general repressor cellular metabolism suppress cellular             pH 5.5 described previously.22 The drug exposure carried out <br /> metabolic activity facilitate persister formation.16 PhoU         period 3 &#226;&#8364;&#8220;9 days 378C shaking. Aliquots bacterial <br /> ubiquitous protein present virtually bacterial species, includ-    cultures exposed drug taken different timepoints and <br /> ing M. tuberculosis.16                                                    washed PBS buffer plating 7H11 agar plates cfu count. <br />     M. tuberculosis, notorious ability persist <br /> in vivo despite antibiotic treatment, PhoU homologues,            Survival persistence DphoY1 DphoY2 mutants <br /> PhoY1 PhoY2,16 share 63.4% amino acid identity               mouse model <br /> each other. PhoY1 PhoY2 have, respectively, 40% 44% <br /> homology E. coli PhoU. The role PhoY1 PhoY2 per-         Six-week-old female BALB/c mice (NCI, Frederick, MD, USA) infected <br />                                                                           tail vein M. tuberculosis strain H37Rv, DphoY1 mutant, <br /> sistence M. tuberculosis unclear. In study, con- <br />                                                                           DphoY2 mutant respective mutant complemented strains (all <br /> structed mutants PhoU homologues phoY1 phoY2 and <br />                                                                            1&#195;&#8212;104 cfu) 100 mL PBS/0.05% Tween 80 using low dose <br /> evaluated role PhoY1 PhoY2 persistence               latent infection model described previously.23 Mice (five mice per <br /> M. tuberculosis. We M. tuberculosis phoY2 equiv-         group) infected different mycobacterial strains were <br /> alent E. coli phoU inactivation phoY2 phoY1        housed BSL-3 animal facility. After 8 weeks infection, mice were <br /> caused defect persistence phenotype including increased          sacrificed infected organs (lungs spleens) homogen- <br /> susceptibility antibiotics decreased persister formation        ized PBS/0.05% Tween 80, homogenates appropriate <br /> vitro, reduced persistence mouse model,                 dilutions plated 7H11 plates containing 10% ADC the <br />  <br />  <br />  <br /> 1238 <br />  PhoU homologue PhoY2 involved TB persistence                                                                                      JAC <br /> Table 1. Bacterial strains, plasmids, phage primers used study <br />  <br />                                                                    Description                                              Source reference <br />  <br /> Strains <br />   E. coli HB101              F2 hsdS20 (rB2 mB) supE44 ara-14 galK-2 lacY1 proA2 rpsL20 (Smr) xyl-5 mtl-1&#226;&#8364;&#8220;recA13      ATCC <br />   M. smegmatis mc2155        high-frequency transformation mutant M. smegmatis ATCC 607                            W. R. Jacobs Jr <br />   M. tuberculosis H37Rv      wild-type strain                                                                         ATCC <br />  <br /> Plasmids <br />   p0004s                     hygromycin resistance plasmid                                                            W. R. Jacobs Jr <br />   pMV261                     E. coli&#226;&#8364;&#8220;Mycobacteria shuttle vector                                                      C. K. Stover <br />  <br /> Phage <br />   phAE159                    temperature-sensitive phage mycobacteria                                             W. R. Jacobs Jr <br />  <br /> Primers <br />    Y1KLL                     5&#226;&#8364;&#178; -TTTTTTTTCCATAAATTGGGAAAGCGACGACACCTCCAAGC-3&#226;&#8364;&#178;                                           phoY1 knockout <br />    Y1KLR                     5&#226;&#8364;&#178; -TTTTTTTTCCATTTCTTGGAACGCTTCCTTTTCGACTTGGG-3&#226;&#8364;&#178;                                           phoY1 knockout <br />    Y1KRL                     5&#226;&#8364;&#178; -TTTTTTTTCCATAGATTGGCGTTGCTGGGTCGTTTCTTTGA-3&#226;&#8364;&#178;                                           phoY1 knockout <br />    Y1KRR                     5&#226;&#8364;&#178; -TTTTTTTTCCATCTTTTGGCACGGATATCACGTTGGGGTAC-3&#226;&#8364;&#178;                                           phoY1 knockout <br />    Y2KLL                     5&#226;&#8364;&#178; -TTTTTTTTCCATAAATTGGCCCGCGTACCTCCGACATGAAG-3&#226;&#8364;&#178;                                           phoY2 knockout <br />    Y2KLR                     5&#226;&#8364;&#178; -TTTTTTTTCCATTTCTTGGTGGCGCTCACAATGGCTCTGAG-3&#226;&#8364;&#178;                                           phoY2 knockout <br />    Y2KRL                     5&#226;&#8364;&#178; -TTTTTTTTCCATAGATTGGGCCGATTCTACGAGCGCTTTGC-3&#226;&#8364;&#178;                                           phoY2 knockout <br />    Y2KRR                     5&#226;&#8364;&#178; -TTTTTTTTCCATCTTTTGGGCTGGCTGGCACGGATAACTGA-3&#226;&#8364;&#178;                                           phoY2 knockout <br />    Y1S                       5&#226;&#8364;&#178; -CGACCCCGTTGACGCACGCCGA-3&#226;&#8364;&#178;                                                              junction PCR <br />    Y1A                       5&#226;&#8364;&#178; -AGCGGTGTGCTGAAGTCGTGGG-3&#226;&#8364;&#178;                                                              junction PCR <br />    Y2S                       5&#226;&#8364;&#178; -ACGGACACCTTGTTCAACCTCA-3&#226;&#8364;&#178;                                                              junction PCR <br />    Y2A                       5&#226;&#8364;&#178; -CGTGCGAACCTACCAGAGCCT-3&#226;&#8364;&#178;                                                               junction PCR <br />    SacA                      5&#226;&#8364;&#178; -TGGTGGACCTCGACGACCCTAGA-3&#226;&#8364;&#178;                                                             junction PCR <br />    HygS                      5&#226;&#8364;&#178; -TTCGAGGTGTTCGAGGAGACCCC-3&#226;&#8364;&#178;                                                             junction PCR <br />    Y1CS                      5&#226;&#8364;&#178; -CGCGGAATTCCAGCCTGTTGAGCCCGATAA-3&#226;&#8364;&#178;                                                      phoY1 complementation <br />    Y1CA                      5&#226;&#8364;&#178; -CGCGAAGCTTCGATACAGGTGCACAACCGAA-3&#226;&#8364;&#178;                                                     phoY1 complementation <br />    Y2CS                      5&#226;&#8364;&#178; -CGCGGAATTCGCACCAGCAGGTTACGACGA-3&#226;&#8364;&#178;                                                      phoY2 complementation <br />    Y2CA                      5&#226;&#8364;&#178; -CGCGAAGCTTCTTCTCCAACCCGAACCAGA-3&#226;&#8364;&#178;                                                      phoY2 complementation <br />  <br />  <br /> antibiotic cocktail PANTA (Becton Dickinson, Sparks, MDk, USA) prevent    wild-type phoY1 phoY2 knockout mutants, <br /> contamination. Plates incubated 378C 5% CO2 environment         indicating successful construction DphoY1 DphoY2 <br /> for 4 weeks cfu counts determined. The Johns Hopkins Uni-        mutants M. tuberculosis. <br /> versity Animal Care Use Committee approved animal procedures. <br />  <br />  <br /> Statistical treatment                                                        Inactivation M. tuberculosis PhoU homologue PhoY2 <br /> Pairwise comparison cfu data statistical significance         PhoY1 caused increased susceptibility <br /> performed using Student&#226;&#8364;&#8482;s t-test.                                            TB drugs <br />                                                                              Since E. coli phoU mutant defect persister formation <br /> Results discussion                                                       demonstrated increased susceptibility antibiotics a <br />                                                                              reduced number persisters,16 subjected phoY1 and <br /> Construction DphoY1 DphoY2 mutants <br />                                                                              phoY2 mutants antibiotic susceptibility tests persister <br /> of M. tuberculosis H37Rv                                                     assays described Materials methods section. Inter- <br /> To determine effect <span id='am-164' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-165' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-177' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-181' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-186' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-200' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-210' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-213' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-222' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-229' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-237' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-238' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-239' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-240' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span>mutation</span> phoY1 phoY2                estingly, inactivation phoY2 caused increased susceptibility to <br /> persistence phenotype M. tuberculosis, constructed               TB drugs rifampicin pyrazinamide compared wild- <br /> knockout mutant DphoY1::hyg DphoY2::hyg alleles using                    type H37Rv MIC MBC experiments (see Table 2). <br /> specialized transduction temperature-sensitive phage                Specifically, MICs rifampicin pyrazinamide the <br /> phAE159 described Materials methods section.                   phoY2 mutant decreased 4-fold 2-fold, respectively, 7H9 <br /> Hygromycin-resistant colonies obtained, sug-                 liquid medium. The MBC rifampicin phoY2 mutant <br /> gestive double-crossover gene replacement event. Junction               4-fold parent strain H37Rv the <br /> PCR used confirm mutant genotype mutant                   MBC pyrazinamide remained unchanged (Table 2). However, <br /> alleles wild-type strain H37Rv control. The 666 bp             inactivation phoY1 did significantly alter susceptibility to <br /> (phoY1) 642 bp (phoY2) fragments observed                    rifampicin pyrazinamide MIC MBC experiments. <br />  <br />  <br />                                                                                                                                              1239 <br />  Shi Zhang <br />  <br />  <br />  <br /> Decreased persisters PhoY2 mutant PhoY1                          comparison defect persisters phoY2 <br /> mutant pyrazinamide rifampicin exposure                            mutant possible (data shown). In drug-free <br />                                                                             control, significant decrease cfu values the <br /> To determine effect pyrazinamide rifampicin the <br />                                                                             phoY2 phoY1 mutants control strain H37Rv, indicating <br /> persister survival phoY1 phoY2 mutants, subjected <br />                                                                             loss persisters rifampicin pyrazinamide <br /> stationary phase cultures parent strain H37Rv the <br />                                                                             exposure phoY2 mutant specific defect in <br /> above mutants pyrazinamide (200 mg/L) pH 5.6 rifam- <br />                                                                             phoY2 non-specific cell death the <br /> picin (8 mg/L) pH 7.0, determined cfu values 0, 3, 9 <br />                                                                             <span id='am-1' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span>-limiting conditions exposure drug. These <br /> and 17 days exposure. No significant difference survival <br />                                                                             results suggest PhoY2, PhoY1, equivalent of <br /> between phoY1 phoY2 mutants parent strain <br />                                                                             E. coli PhoU M. tuberculosis. It note the <br /> H37Rv observed 3 days exposure pyrazina- <br />                                                                             defect persister survival phoY2 obvious the <br /> mide rifampicin (P.0.05). After 9 days pyrazinamide rifam- <br />                                                                             earlier timepoint 3 day drug exposure seen only <br /> picin exposure, difference survival between <br />                                                                             extended exposure 9 days. This consistent with <br /> phoY1 mutant parent strain H37Rv, survival of <br />                                                                             previous findings E. coli phoU mutant, which, the <br /> the phoY2 mutant greatly decreased persisters <br />                                                                             drug exposure persister assay, require relatively long <br /> were detectable (detection limit 100 bacteria) (Table 3). <br />                                                                             time persistence defect demonstrated.16 Future <br /> However, day 17, viable bacteria killed pyrazina- <br />                                                                             studies needed determine PhoY2 mutant <br /> mide mutants parent control strain H37Rv <br />                                                                             defective persistence TB drugs fluoro- <br />                                                                             quinolones aminoglycosides. <br />  <br /> Table 2. MIC MBC values (mg/L) phoY1 phoY2 mutants <br /> compared parent strain H37Rv                                           PhoY2 mutant defect persistence mouse <br />                                                                             model TB infection <br />                                          Strain <br />                                                                             To verify persister-defective phenotype the <br />                  H37Rv            phoY1 mutant           phoY2 mutant <br />                                                                             M. tuberculosis phoY2 mutant shown above, evaluated <br />                                                                             persistence phoY2 phoY1 mutants their <br /> Drug          MIC     MBC         MIC             MBC    MIC       MBC      respective complemented strains parent control <br />                                                                             strain H37Rv using low dose latent TB infection mouse model <br /> PZA pH 5.9   200     400      200             400       100       400       described Materials methods section. Mice were <br /> RIF            0.1     0.2      0.05 &#226;&#8364;&#8220;0.1       0.2       0.025     0.05    infected comparably low numbers mycobac- <br />                                                                             terial strains ( 104 bacilli) described Materials and <br /> PZA, pyrazinamide; RIF, rifampicin.                                         methods section. The survival various mycobacterial strains <br /> The starting inocula used H37Rv, phoY1 phoY2 mutants were:          determined 8 weeks infection. As seen in <br /> 5&#195;&#8212;105, 6.3&#195;&#8212;105 6.3&#195;&#8212;105, respectively. MIC/MBC testing per-          Table 4, PhoY2 mutant able survive persist <br /> formed 7H9 liquid medium described Materials               mouse lungs spleens shown  10- to <br /> methods section.                                                            30-fold decrease cfu counts compared virulent <br />  <br /> Table 3. PhoY2 mutant PhoY1 mutant reduced persisters vitro <br />  <br />                                                                                               Bacterial count (cfu/mL) <br />  <br /> Drug concentration                       Strain                          start                        day 3                         day 9 <br />  <br /> Pyrazinamide (pH 5.6, 7H9 ADC) <br />   200 mg/L                        H37Rv                            3.1+0.10&#195;&#8212;106                   3.1+0.45&#195;&#8212;105                  5.3+0.15&#195;&#8212;103 <br />   200 mg/L                        H37Rv DphoY1                     3.2+0.17&#195;&#8212;106                   4.3+0.50&#195;&#8212;105                  3.3+0.15&#195;&#8212;103 <br />   200 mg/L                        H37Rv DphoY2                     2.4+0.79&#195;&#8212;106                  4.83+0.06&#195;&#8212;105                    0a <br />   0 mg/L                          H37Rv                            3.1+0.10&#195;&#8212;106                   6.9+0.46&#195;&#8212;105                 1.33+0.15&#195;&#8212;105 <br />   0 mg/L                          H37Rv DphoY1                     3.2+0.17&#195;&#8212;106                  2.07+0.47&#195;&#8212;106                 3.97+0.25&#195;&#8212;105 <br />   0 mg/L                          H37Rv DphoY2                     2.4+0.79&#195;&#8212;106                  4.77+1.05&#195;&#8212;105                 2.77+0.15&#195;&#8212;105 <br />  <br /> Rifampicin (pH 7.0, 7H9 ADC) <br />    200 mg/L                        H37Rv                           3.1+0.10&#195;&#8212;108                  3.37+0.51&#195;&#8212;105                 1.67+0.25&#195;&#8212;104 <br />    200 mg/L                        H37Rv DphoY1                    3.2+0.17&#195;&#8212;108                  4.97+0.70&#195;&#8212;105                 3.13+0.31&#195;&#8212;104 <br />    200 mg/L                        H37Rv DphoY2                    2.4+0.79&#195;&#8212;108                  2.27+0.57&#195;&#8212;105                    0a <br />    0 mg/L                          H37Rv                           3.1+0.10&#195;&#8212;108                  1.33+0.40&#195;&#8212;109                  3.5+0.26&#195;&#8212;108 <br />    0 mg/L                          H37Rv DphoY1                    3.2+0.17&#195;&#8212;108                   2.0+0.35&#195;&#8212;109                 3.57+0.32&#195;&#8212;108 <br />    0 mg/L                          H37Rv DphoY2                    2.4+0.79&#195;&#8212;108                  1.37+0.32&#195;&#8212;109                  3.0+0.40&#195;&#8212;108 <br />  <br /> a <br /> Below detection limit 100 bacteria. <br />  <br />  <br />  <br /> 1240 <br />  PhoU homologue PhoY2 involved TB persistence                                                                                     JAC <br />                 Table 4. Survival phoY1 phoY2 mutants complemented strains mice <br />  <br />                                                           Beginning cfu                 cfu/spleen                  cfu/lung <br />  <br />                 H37Rv                                    0.84+0.11&#195;&#8212;104              3.03+0.19&#195;&#8212;103               1.20+0.10&#195;&#8212;102 <br />                 H37Rv DphoY1                             1.18+0.09&#195;&#8212;104              7.39+0.48&#195;&#8212;103               3.73+0.27&#195;&#8212;102 <br />                 H37Rv DphoY1 complemented                1.25+0.35&#195;&#8212;104              4.38+0.85&#195;&#8212;103               3.81+0.92&#195;&#8212;102 <br />                 H37Rv DphoY2                             1.13+0.27&#195;&#8212;104              1.71+1.16&#195;&#8212;102*               1.6+1.0&#195;&#8212;101* <br />                 H37Rv DphoY2 complemented                1.35+0.40&#195;&#8212;104              5.82+0.62&#195;&#8212;103               4.89+0.40&#195;&#8212;102 <br />  <br />                 The phoY2 mutant 10- 30-fold fewer cfu lungs spleen control parent strain H37Rv <br />                 (*P,0.05 compared cfu control H37Rv). Complementation phoY2 mutant restored level <br />                 persistence parent strain H37Rv. There significant difference survival persistence <br />                 lungs spleen H37Rv, phoY1 mutant complemented strains (P. 0.05). <br />  <br />  <br />  <br /> parent strain H37Rv (P,0.05), PhoY1 mutant sur-               phenotype TB drugs aminoglycosides qui- <br /> vived persisted H37Rv control strain. Interest-        nolones, long-term persistence phoY2 mutant the <br /> ingly, complementation PhoY2 mutant wild-type             mouse model elucidate mechanism which <br /> phoY2 gene restored persistence phenotype PhoY2                phoY2 mediates persistence M. tuberculosis. <br /> mutant wild-type level H37Rv spleens                    In conclusion, shown M. tuberculosis PhoU <br /> lungs (Table 4). This experiment validates PhoY2                 homologue PhoY2 PhoY1 equivalent E. coli <br /> mutant vitro defect persister survival           PhoU demonstrated increased susceptibility TB drugs <br /> drug exposure assays shown above, exhibited                defect persistence mouse model. This is <br /> in vivo persistence defect mouse model (Table 4).                  study confirms role PhoU persistence in <br />     Our data suggest PhoY2 mutation does alter persistence           different organism (i.e. M. tuberculosis) E. coli. Studies <br /> as shown persister drug exposure assay, mouse study            currently underway address detailed mechanisms of <br /> and MIC/MBC values PhoY2 mutant. There sig-           PhoU PhoY2 mediates persister formation. The identifi- <br /> nificant debate regarding persister mutants              cation PhoY2 involved mycobacterial persistence <br /> alteration MIC/MBC values. It proposed persister         significant finding implications under- <br /> mutants alter MIC affect persistence.24           standing mechanism persistence development <br /> However, necessarily true mutation persis-          new drugs vaccines target persister organisms for <br /> ter genes affect antibiotic susceptibility         improved control TB. <br /> persisters shown persister assays growing bac- <br /> teria shown MIC/MBC tests case PhoU mutation16 <br /> and SucB UbiF mutations.25 In addition, found <br /> that mutants defect persistence have <br />                                                                           Acknowledgements <br /> altered MIC/MBC values (J. Chen Y. Zhang, unpublished data).          We grateful Bill Jacobs providing mycobacterial plasmids and <br />                                                                           phages. <br />     It demonstrated PhoU expression correlated <br /> with persister formation expressed stationary <br /> phase aged cultures <span id='am-2' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span>-limiting conditions16,26 <br /> or overexpressed biofilms E. coli.27 In PhoU overexpres-        Funding <br /> sion study using arabinose-inducible pBAD vector,           This work supported NIH grant AI44063. <br /> overexpression phoU caused increased persister formation in <br /> log phase E. coli cultures, overexpression control genes <br /> ruvA, fur rcsB involved L-form formation28 same <br /> vector did (W. Shi Y. Zhang, unpublished observation).            Transparency declarations <br /> Studies underway assess controlled overexpres-             None declare. <br /> sion phoY2 leads increased persister formation in <br /> M. tuberculosis. More recently, consistent previous <br /> finding PhoU important persister formation                 References <br /> E. coli,16 Lee et al. 29 PhoU played critical role        1 WHO. World Health Organization Tuberculosis (TB). http://www.who.int/ <br /> persister phenotype Pseudomonas putida shown higher              tb/en/ (9 October 2009, date accessed). <br /> susceptibility decreased persisters phoU mutant. It            2 CDC. Emergence Mycobacterium tuberculosis extensive <br /> is note phoY2 (Rv0821c) significantly             resistance second-line drugs - worldwide, 2000-2004. MMWR Morb <br /> up-regulated 96 h <span id='am-5' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span> starvation persistence model           Mortal Wkly Rep 2006; 55: 301&#226;&#8364;&#8220;5. <br /> M. tuberculosis,30 suggesting phoY2 important             3 Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant <br /> mycobacterial persistence. Our findings study provide             tuberculosis cause death patients co-infected with <br /> further evidence phoY2 involved persistence M. tuber-       tuberculosis HIV rural area South Africa. Lancet 2006; 368: <br /> culosis. Future studies needed determine persister             1575&#226;&#8364;&#8220; 80. <br />  <br />  <br />  <br />                                                                                                                                            1241 <br />  Shi Zhang <br />  <br />  <br />  <br /> 4 WHO. XDR-TB, Extensively Drug-Resistant Tuberculosis. http://www.who.       19 Dahl JL, Kraus CN, Boshoff HI et al. The role RelMtb-mediated <br /> int/tb/challenges/xdr/en/index.html (21 September 2009, date             adaptation stationary phase long-term persistence of <br /> accessed).                                                                    Mycobacterium tuberculosis mice. Proc Natl Acad Sci USA 2003; 100: <br /> 5 McDermott W. Microbial persistence. Yale J Biol Med 1958; 30: 257&#226;&#8364;&#8220;91.       10026&#226;&#8364;&#8220;31. <br /> 6 Zhang Y. The magic bullets tuberculosis drug targets. Annu Rev          20 Bardarov S, Kriakov J, Carriere C et al. Conditionally replicating <br /> Pharmacol Toxicol 2005; 45: 529&#226;&#8364;&#8220; 64.                                          mycobacteriophages: transposon delivery to <br />                                                                               Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1997; 94: 10961&#226;&#8364;&#8220; 6. <br /> 7 Mitchison D. The search new sterilizing anti-tuberculosis drugs. <br /> Front Biosci 2004; 9: 1059&#226;&#8364;&#8220; 72.                                               21 Zhang Y, Garbe T, Young D. Transformation katG restores <br />                                                                               isoniazid-sensitivity Mycobacterium tuberculosis isolates resistant a <br /> 8 Hobby GL, Meyer K, Chaffee E. Observations mechanism of <br />                                                                               range drug concentrations. Mol Microbiol 1993; 8: 521&#226;&#8364;&#8220;4. <br /> action penicillin. Proc Soc Exp Biol NY 1942; 50: 281&#226;&#8364;&#8220; 5. <br />                                                                               22 Wade MM, Zhang Y. Effects weak acids, UV proton motive force <br /> 9 Bigger JW. Treatment staphylococcal infections penicillin. <br />                                                                               inhibitors pyrazinamide activity Mycobacterium tuberculosis <br /> Lancet 1944; 244: 497&#226;&#8364;&#8220; 500. <br />                                                                               vitro. J Antimicrob Chemother 2006; 58: 936&#226;&#8364;&#8220; 41. <br /> 10 Balaban NQ, Merrin J, Chait R et al. Bacterial persistence a <br />                                                                               23 Orm <br /> </body></html>